Stephens & Co. Maintains Equal-Weight on Lifecore Biomedical, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Jacob Johnson maintains an Equal-Weight rating on Lifecore Biomedical (NASDAQ:LFCR) and raises the price target from $8 to $9.
September 01, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stephens & Co. maintains an Equal-Weight rating on Lifecore Biomedical and raises the price target from $8 to $9, which could potentially attract investors.
The raised price target by Stephens & Co. indicates a positive outlook for Lifecore Biomedical. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100